Please ensure Javascript is enabled for purposes of website accessibility

3 Reasons to Buy Novavax Stock After Its Huge Pullback

By Keith Speights - Mar 10, 2021 at 6:04AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This biotech stock looks like a better buy now than it did a few weeks ago.

Novavax (NVAX 17.46%) got off to a fantastic start this year. By early February, the stock had soared more than 180% year to date. But it hasn't been such a great story since then. Novavax's shares have fallen around 50% from the high set a month ago.

I don't think it's time to throw in the towel on the biotech by any means. Here are three reasons to buy Novavax stock after its huge pullback.

Gold dollar sign surrounded by coronavirus

Image source: Getty Images.

1. Near-term catalysts

The only thing struggling biotech stocks need to turn things around is a positive catalyst or two. And Novavax probably has several of them on the way.

In late January, Novavax reported great results from a late-stage study of COVID-19 vaccine NVX-CoV2373 conducted in the U.K. The company stated in its Q4 update last week that it expects to file for U.K. authorization of the experimental vaccine in early second quarter. It seems likely that NVX-CoV2373 will win this authorization, which should provide a nice boost to Novavax's share price.

An even bigger catalyst could come soon after that. If the U.S. Food and Drug Administration (FDA) allows Novavax to file for U.S. emergency use authorization (EUA) based on its U.K. data, the biotech's COVID-19 vaccine could become available to Americans in May. 

What happens if the FDA doesn't permit Novavax to use its U.K. data as the basis for its EUA filing? No worries. The company recently completed enrollment in its late-stage study of NVX-CoV2373 in the U.S. and Mexico. If it's required to use data from this study for its submission, EUA in the U.S. should still be on the way by June or July.

2. Attractive valuation

Thanks to the big sell-off for Novavax, the company's market now stands below $12 billion. I view this as an attractive valuation.

The consensus among Wall Street analysts is that Novavax will make nearly $5 billion in sales this year. That estimate doesn't seem farfetched at all, in my opinion. The company already has supply deals lined up for around 300 million doses. In addition, the company has an agreement with the Serum Institute of India for 1.1 billion doses.

Novavax's current market cap and that revenue target gives the company a forward price-to-sales (P/S) multiple of 2.4. By comparison, BioNTech currently trades at 2.7 times expected sales. Moderna's forward P/S multiple is close to 3.1.

Sure, both BioNTech and Moderna have larger pipelines than Novavax does. However, Novavax has another candidate that's already sailed through late-stage testing while the other two companies don't have a candidate waiting in the wings in a similar position.

3. Long-term opportunities

That leads us to arguably the best reason to buy Novavax stock: The biotech's long-term prospects. NVX-CoV2373 is an important component to those prospects. But so is Novavax's other lead candidate, flu vaccine NanoFlu.

Immediately prior to the COVID-19 pandemic, NanoFlu ranked as the primary reason behind investors' interest in Novavax. In March 2020, the company reported overwhelmingly positive results from a late-stage study of the flu vaccine in a head-to-head comparison against Sanofi's FluZone Quadrivalent. 

Novavax is looking at several possibilities for commercializing NanoFlu. These include featuring it as a combination vaccine with NVX-CoV2373, with its experimental respiratory syncytial virus (RSV) vaccine, and perhaps even putting all three vaccines together.

In addition, the biotech plans to initiate a clinical study evaluating candidates targeting new coronavirus variants, including a bivalent vaccine, in mid-2021. These efforts could position Novavax well in the COVID-19 vaccine market going forward.

Novavax still faces risks that its vaccines won't ultimately win authorization or approval. However, I don't think those risks are too worrisome considering the solid late-stage results reported for both NVX-CoV2373 and NanoFlu. My prediction is that the stock will finish the year valued well above its current price.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
$55.29 (17.46%) $8.22
Sanofi Stock Quote
$55.15 (-0.63%) $0.35
Moderna, Inc. Stock Quote
Moderna, Inc.
$147.66 (8.73%) $11.86
BioNTech SE Stock Quote
BioNTech SE
$166.96 (5.57%) $8.81

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.